

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Simcere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

VOLUNTARY ANNOUNCEMENT

NEW DRUG APPLICATION OF SUVEMCITUG FOR INJECTION ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by Simcere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, on March 15, 2024, the New Drug Application of Suvemcitug for injection has been accepted by the National Medical Products Administration of China (“**NMPA**”). The indication is Suvemcitug combined with chemotherapy for the treatment of recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.

ABOUT SUVEMCITUG

Suvemcitug is a new-generation recombinant humanized anti-VEGF rabbit monoclonal antibody developed by the Group and Apexigen, Inc. (“**Apexigen**”, now part of Pyxis Oncology, Inc.) Pre-clinical studies have shown that Suvemcitug has higher affinity and anti-tumor efficacy than Bevacizumab at the same dose in multiple tumor models. The phase Ib clinical studies of Suvemcitug conducted in China for the treatment of ovarian cancer preliminary demonstrated its favorable safety profile and efficacy signals. On January 3, 2024, the phase III clinical trial of Suvemcitug for injection combined with chemotherapy versus placebo combined with chemotherapy in patients with recurrent, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (the SCORES study) met the primary endpoint. On March 11, 2024, the Group submitted the New Drug Application of Suvemcitug for injection to the NMPA.

ABOUT APEXIGEN

Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology. On August 23, 2023, Apexigen is acquired by Pyxis Oncology, Inc. (a Nasdaq listed public company in the United States – stock code: PYXS.NASDAQ). Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers, and is efficiently building next-generation therapeutics that hold the potential for mono and combination therapies.

ABOUT THE COMPANY

The Company is an innovation and R&D-driven pharmaceutical company and has established a “State Key Laboratory of Neurology and Oncology Drug Development”. The Company focuses on the therapeutic areas of oncology, nervous system, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of “providing today’s patients with medicines of the future”. Driven by its in-house R&D efforts and synergistic innovation, the Company has established strategic cooperation partnerships with many innovative companies and research institutes.

By order of the Board
Sincere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, March 15, 2024

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director, Mr. TANG Renhong, Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; and Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.